PCH
EWTX icon

Polar Capital Holdings’s Edgewise Therapeutics EWTX Stock Holding History

Polar Capital Holdings’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-975,000
Closed -$12.8M – 271
2025
Q2 		$12.8M Buy
975,000
+725,000
+290% +$10.5M 0.07% 175
2025
Q1 		$5.5M Buy
+250,000
New +$6.56M 0.03% 224

Other funds holding EWTX

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Polar Capital Holdings's EWTX Position: Q3 2025 in Review

Polar Capital Holdings sold out of Edgewise Therapeutics (EWTX) in Q3 2025, closing a stake of 975,000 shares — an estimated $12.8M sold.

Polar Capital Holdings first reported a position in EWTX in Q1 2025 and held it in 2 quarters. The position peaked at $12.8M in Q2 2025. 173 funds tracked by Wall St. Rank hold EWTX as of Q3 2025.

  • Polar Capital Holdings reported no remaining Edgewise Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Polar Capital Holdings sold 975,000 Edgewise Therapeutics shares in Q3 2025, an estimated $12.8M.
  • Polar Capital Holdings first reported a position in Edgewise Therapeutics in Q1 2025 and held it in 2 quarters.
  • Polar Capital Holdings's Edgewise Therapeutics position peaked at $12.8M in Q2 2025.
  • 173 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q3 2025.

Based on Polar Capital Holdings's 13F filing for Q3 2025, filed 14 Nov 2025.